A plasma protein classifier for predicting amyloid burden for preclinical Alzheimer's disease by Ashton, NJ et al.
Ashton et al., Sci. Adv. 2019; 5 : eaau7220     6 February 2019
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
1 of 12
N E U R O S C I E N C E
A plasma protein classifier for predicting amyloid 
burden for preclinical Alzheimer’s disease
Nicholas J. Ashton1,2,3,4, Alejo J. Nevado-Holgado5, Imelda S. Barber5, Steven Lynham6,  
Veer Gupta7,8,9, Pratishtha Chatterjee7,10,11, Kathryn Goozee10,11,12,13, Eugene Hone7,8, 
Steve Pedrini7,8, Kaj Blennow3,14, Michael Schöll3,4, Henrik Zetterberg3,14,15,16, Kathryn A. Ellis17, 
Ashley I. Bush8,18, Christopher C. Rowe19, Victor L. Villemagne19, David Ames17,20, Colin L. Masters18, 
Dag Aarsland1,2,21, John Powell1,2, Simon Lovestone5, Ralph Martins7,8,10,11, Abdul Hye1,2*
A blood-based assessment of preclinical disease would have huge potential in the enrichment of participants for 
Alzheimer’s disease (AD) therapeutic trials. In this study, cognitively unimpaired individuals from the AIBL and 
KARVIAH cohorts were defined as A negative or A positive by positron emission tomography. Nontargeted 
proteomic analysis that incorporated peptide fractionation and high-resolution mass spectrometry quantified 
relative protein abundances in plasma samples from all participants. A protein classifier model was trained to 
predict A-positive participants using feature selection and machine learning in AIBL and independently assessed 
in KARVIAH. A 12-feature model for predicting A-positive participants was established and demonstrated high accu-
racy (testing area under the receiver operator characteristic curve = 0.891, sensitivity = 0.78, and specificity = 0.77). 
This extensive plasma proteomic study has unbiasedly highlighted putative and novel candidates for AD pathology 
that should be further validated with automated methodologies.
INTRODUCTION
The search for a blood-based signature that can predict the onset of 
Alzheimer’s disease (AD) has gathered considerable momentum in 
recent years. Much effort has been dedicated to the discovery of 
single- and multianalyte protein markers to differentiate AD from 
age-matched cognitively unimpaired individuals [reviewed in (1)]. A 
major concern for the field has been the lack of reproducibility for these 
putative candidates, and these inconsistencies might be explained 
by substantial preanalytical variations among research cohorts. 
However, it is likely that the inherent heterogeneity of AD is partially 
accountable for the failure in replicating “case-versus-control” studies 
(2). Given the long preclinical phase in AD where the accumulation 
of pathology is thought to begin 15 to 20 years before clinical pre-
sentation (3), a considerable proportion of seemingly unimpaired 
individuals will harbor substantial amyloid  (A) pathology. Con-
sequently, within a clinical diagnosis–dependent study design, indi-
viduals in the preclinical disease phase would be classified as 
“healthy controls,” despite underlying A pathology being present. 
Increasingly, “endophenotype” studies are using surrogate markers 
of neocortical A burden [positron emission tomography (PET) 
imaging or cerebrospinal fluid (CSF) measures] to identify blood-
based biomarkers indicative of ongoing disease pathogenesis. Tools 
to identify and monitor A burden are of critical importance, given 
the increased focus on anti-A therapeutics. Retrospective imaging 
from these early trials confirmed that a considerable proportion of 
recruited participants did not exhibit the target pathology or were 
too advanced in the disease course (4). This was a major concern and 
highlighted the importance of a biomarker-driven participant selec-
tion, and consequently, these trials are targeting individuals with 
biomarker evidence of pathology with no or little cognitive deficits. 
This selection process, based on PET imaging and/or CSF A, is likely 
to be unfeasible to implement widely, particularly for population- based 
screening. Therefore, a minimally invasive and accessible blood- 
based prediction of A burden would be of considerable use in thera-
peutic stratification and clinical management at the earliest stage.
Ultrasensitive immunoassay and immunoprecipitation mass spec-
trometry (MS) methods have recently reported plasma A ratios as 
being able to predict A PET (5, 6). However, there has been limited 
investigation using untargeted methods in the discovery of novel blood 
markers that could reflect A burden. Studies using A endophenotype 
stratification have seldom investigated preclinical AD and have used 
a range of technologies, including two-dimensional gel electropho-
resis (7, 8) and immunoassay panels (9, 10), but these approaches 
have limitations (e.g., predetermined targets, large sample volumes, 
and large variability). At the discovery level, MS has the key advan-
tage of unbiased measurement of features present within a sample 
without prior knowledge of its contents. This enables MS to be com-
patible with a hypothesis-free investigation, the results of which 
could be confirmed using targeted proteomics. The foremost criti-
cism of shotgun MS workflows is poor sensitivity owing to the large 
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dynamic range of protein abundances, which results in an inade-
quate coverage of the plasma proteome. The marked improvement 
in MS technology over recent years has renewed the interest in un-
targeted plasma proteins in many disease areas, and combined with 
immunodepletion of highly abundant proteins and extensive frac-
tionation methods, it is possible to identify more than 1000 proteins 
(11). With this in mind, the aim of this study was to perform an exten-
sive untargeted proteomic discovery in plasma to predict A burden 
in preclinical disease. We primarily focused on 238 cognitively un-
impaired individuals from the Australian Imaging, Biomarker and 
Lifestyle Flagship Study of Ageing (AIBL) and the Kerr Anglican Re-
tirement Village Initiative in Ageing Health (KARVIAH) studies who 
had undergone PET to determine their A status. Moreover, we took 
a comprehensive approach to replicating our findings in an indepen-
dent sample set using the same methodological approach.
RESULTS
Subject demographics
The demographic and clinical characteristics of the cognitively 
unimpaired individuals are presented in Table 1. In AIBL, 100 
participants were classified as A negative (A−) and 44 participants 
as A positive (A+) by 11C-PiB standardized uptake values ratio 
(SUVR) cutoff of 1.4. In KARVIAH, 59 participants were classified as 
A− and 35 participants as A+ by 18FBB (Florbetaben) SUVR cut-
off of 1.35. There was a significant increase in the number APOE 4 
carriers in both A+ groups, and the A+ groups also had a tendency 
to be older. There was no significant difference in cognitive perfor-
mance between A− and A+ groups (Table 1). A secondary analy-
sis included a further 46 AIBL participants with a diagnosis of mild 
cognitive impairment (MCI; n = 21) or AD (n = 25). The character-
istics of the full cohort including these subjects are presented in Table 2.
Plasma protein metrics
A total of 2356 individual protein groups at 5% false discovery rate 
(FDR) were measured across all experiments. The lowest observed 
concentration was 4.3 pg/ml (multiple epidermal growth factor–like 
domains protein 8), with 29% of protein groups measured in this study 
had reported concentrations in a reference database (Human Plasma 
Proteome Project; www.hupo.org/plasma-proteome-project/). A total 
of 560 protein groups were consistently measured across >75% of the 
sample set (table S1), and these protein groups were taken forward for 
statistical evaluation.
Plasma proteins associated with A burden in a  
preclinical disease
A PET SUVR measures from 238 cognitively unimpaired individuals 
(Table 1) were categorized into binary “A−” or “A+” classification, 
and adjusted scores for 560 plasma proteins were analyzed for their 
association with A pathology. A total of 37 protein groups were found 
to be nominally associated with A groups at the uncorrected P value 
of <0.05 (Fig. 1 and table S2A). After Benjamini-Hochberg multiple 
testing correction (FDR), five protein groups remained associated with 
A classification (Q = <0.05; Table 3). An increased expression for 
A A4 precursor protein (APP), neurogenin-2 (NGN2), neurofila-
ment light polypeptide (NfL), and A APP–binding family B member 3 
(APBB3) in A+ individuals was observed with a medium-to-large 
effect size (Fig. 1). A decreased protein expression in the A+ group 
was found for RE1-silencing transcription factor (REST) with a small 
effect size (Cohen’s d = 0.46). After adjusting for the influence of 
APOE genotype, APP, NGN2, and NfL remained statistically increased 
in the A+ group despite a weaker association (Q = <0.05; Table 3). 
Synaptosomal-associated protein 25 (SNAP25) was the only protein 
group to become nominally associated with A burden after APOE 
adjustment but did not pass FDR (Fig. 1 and table S2A). Only four 
protein groups were uniquely significantly associated with A+ 
in cognitively unimpaired individuals: DENN domain-containing 
protein 3 (DENN3), sentrin-specific protease 5 (SENP5), zinc finger 
CCCH domain–containing protein 13 (ZCH13), and cilia- and 
flagella-associated protein 43 (WDR96). In addition, NGN2, 
helicase- like transcription factor (HLTF), forkhead-associated 
domain- containing protein 1 (FHAD1), ribosomal protein S6 kinase 
alpha-3 (RPS6KA3), and signal-induced proliferation-associated 
1–like protein 3 (SIPAIL3) had greater effect sizes in the cognitively 
unimpaired group despite being statistically significant in both 
analyses (Fig. 1).
Plasma proteins associated with A burden including 
individuals with MCI and AD
We then combined an additional 46 participants from AIBL with an 
MCI, and AD diagnosis was included in a secondary analysis (table S3). 
A total of 56 protein groups were found to be statistically different 
between A− and A+ groups at the uncorrected P value of <0.05 
(Fig. 1). After FDR, eight protein groups remained associated with 
A classification (Q = <0.05; table S3A). These included APP, 
NGN2, NfL, APBB3, and REST, with the addition of dynein heavy 
chain 10 (DNAH10), G protein–signaling modulator 2 (GPSM2), 
and secreted phosphoprotein 24 (SPP2).
Most of protein groups had larger effect sizes when including 
A+ individuals with AD/MCI, including APP, NfL, REST, SPP2, 
and NRGN (neurogranin). There were an additional 24 protein 
groups that were statistically significant in the AD/MCI group 
compared with the cognitively unimpaired. However, several of 
these proteins were similar in effect size, and therefore, the reduced 
sample size in the cognitively unimpaired meant that they did 
not reach statistical significance [e.g., prothrombin (F2); Fig. 1]. 
Protein groups that had substantially greater effect in AD/MCI 
were nonreceptor tyrosine-protein kinase (TKY2) and mucin-12 
(MUC12).
Plasma protein classifier for A positivity
Univariate analysis revealed several single plasma protein groups to 
be nominally associated with A classification, with a small number 
of protein groups being strongly associated with A status with 
medium-to-large effect sizes (Tables 3 and 4). While this univariate 
analysis studies associations one protein at a time, classifier methods 
do so with all proteins simultaneously, which enables detecting pro-
teins that are related to disease only when considered in combination 
with other proteins. Owing to this, classifiers are able to achieve the 
greater sensitivity and specificity required for clinical implementation, 
although the proteins they select may not always coincide with those 
found by univariate methods.
The feature selection method “Ridge,” followed by a support vector 
machine (SVM) analysis, was used to create classifiers predicting A+ 
in the AIBL cohort. We used either demographics only [gender, age, 
and APOE ɛ4 count (“demographic data”)] and/or proteins (“full data”). 
Each scenario produced 50 classifier models, with each classifier 
including one additional feature into the model. We tested each 
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classifier in the independent KARVIAH dataset and calculated the 
area under the receiver operator characteristic (ROC) curve (AUC) 
to detect the best model at predicting A positivity in each scenario. 
The optimal model to predict A positivity in cognitively unim-
paired individuals produced a testing AUC of 0.891 [cutoff = 0.63, 
specificity = 0.77, sensitivity = 0.78, positive predictive value (PPV) = 0.85, 
and negative predictive value (NPV) = 0.68; Fig. 2]. This classifier 
included 10 protein features (Table 5) and two demographic fea-
tures (APOE 4 count and age). A classifier that included participants 
with MCI and AD produced a testing AUC of 0.904 (cutoff = 0.687, 
specificity = 0.80, sensitivity = 0.81, PPV = 0.87, and NPV = 0.72; 
Fig. 3). This classifier included one demographic feature (APOE 4 
count) and nine protein features, of which eight proteins were com-
mon with the cognitively unimpaired classifier (Table 6). The opti-
mum demographic data model demonstrated a testing AUC of 0.725 
for the cognitively unimpaired cohort.
DISCUSSION
Current imaging and CSF measurements of A are considered gold 
standards for diagnosis of cerebral AD pathophysiology (12). How-
ever, PET imaging is costly, access to the ligand is limited, and this 
imaging is only available in relatively specialized centers. Therefore, 
it is unlikely to be part of routine clinical assessment of cognitive 
complaints before therapies become available. Conversely, CSF collec-
tion is more readily accessible, less expensive, but generally consid-
ered as invasive with a small risk of mild adverse effects by the public 
or as time consuming by clinicians. Furthermore, neither of these 
gold standards is suitable for population-based screening for identi-
fying high-risk individuals for early intervention before symptom 
onset. Thus, a blood-based measure that accurately reflects AD 
pathology, ideally at the preclinical phase, would have significant 
advantages in therapeutic trials and clinical decisions in prescribing 
A-targeting drugs once available.
In the present study, we used a nontargeted proteomic technique 
that combined extensive prefractionation and high-resolution MS 
to demonstrate a substantial number of individual plasma proteins 
to be nominally associated with A burden in the cognitively unim-
paired. A distinct group of analytes were shown to be highly related 
to A burden, with medium-to-large effect sizes. However, the sub-
stantial overlap of the group-wise distributions suggested that these 
markers alone would not reliably distinguish A burden. Therefore, 
and more notably, using feature selection and SVM, we detailed a 
multianalyte classifier to predict A burden that was replicated 
Table 2. Subject demographics for the mixed diagnosis cohort (AIBL, n = 190; KARVIAH, n = 94). n/a, not available. 
AIBL discovery cohort (11C-PiB) KARVIAH replication cohort (18FBB)
A− A+ P value A− A+ P
Number of subjects (n) 108 82 59 35
A PET SUVR  
[means (SD)] 1.16 (0.1) 2.09 (0.4) 7.44 × 10
−60 1.16 (0.1) 1.70 (0.2) 8.35 × 10−23
Gender; females 
[n (%)] 54 (50.0) 40 (48.7) ns 40 (67.8) 21 (60.0) ns
Age in years  
[means (SD)] 71.17 (7.2) 74.04 (7.7) 0.011 77.5 (5.5) 79.6 (5.3) ns


















APOE 4 carrier [n (%)] 28 (25.9) 54 (65.9) 5.91 × 10−5 6 (10.2) 15 (42.9) 0.001
MMSE [means (SD)] 28.7 (1.4) 26.1 (4.0) 5.96 × 10−7 29.4 (1.6) 29.1 (1.4) ns
Table 1. Subject demographics for cognitively unimpaired individuals (AIBL, n = 144; KARVIAH, n = 94). MMSE, Mini Mental State Examination; ns, not 
significant. 
AIBL discovery cohort (11C-PiB) KARVIAH replication cohort (18FBB)
A− A+ P value A− A+ P value
Number of subjects (n) 100 44 59 35
A PET SUVR  
[means (SD)] 1.16 (0.1) 1.90 (0.3) 1.11 × 10
−54 1.16 (0.1) 1.70 (0.2) 8.35 × 10−23
Gender; females  
[n (%)] 51 (50.0) 21 (50.0) ns 40 (67.8) 21 (60.0) ns
Age in years  
[means (SD)] 70.8 (7.1) 75.5 (6.9) 0.001 77.5 (5.5) 79.6 (5.3) ns
APOE 4 carrier [n (%)] 27 (27) 27 (61.4) 7.70 × 10−4 6 (10.2) 15 (42.9) 0.001
MMSE [means (SD)] 28.9 (1.2) 28.5 (1.3) ns 29.4 (1.6) 29.1 (1.4) ns
 o
n







Ashton et al., Sci. Adv. 2019; 5 : eaau7220     6 February 2019
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
4 of 12
by the identical proteomic workflow in an independent cohort with 
high accuracy. Although the statistical workflow is complex, this 
complexity was only necessary when seeking which was the minimal 
combination of proteins that produced the most accurate biomarker. 
Once the identity of these proteins has been established, which was 
one of the objectives of the paper, the classifier is reduced to a sim-
ple weighted sum. Namely, each of these selected proteins is multi-
plied by a number (so-called weight) and the results added together. 
If this sum surpasses a threshold value (so-called decision threshold), 
then the subject is classified as A+. We have demonstrated the possi-
ble clinical utility of these plasma biomarker panels in two practical 
scenarios: one preclinical and one mixed diagnosis cohort (AD and 
MCI). In both scenarios, the high accuracies demonstrate the poten-
tial of a blood-based screen to precede or complement CSF and A 
PET scans in participant selection for clinical trials. Predicting A 
burden in the mixed cohort was superior (AUC = 0.904, specificity = 
0.80, and sensitivity = 0.81), but when assessing A burden at the 
preclinical stage, an almost identical classifier showed very sim-
ilar diagnostic performance (AUC = 0.891, specificity = 0.77, and 
sensitivity = 0.78).
The proteins included in this predictive panel represent a diverse 
array of pathways, which most are not directly related to A pathology 
per se. The serine protease prothrombin (a precursor to thrombin) 
was the highest ranked feature in the cognitively unimpaired cohort. 
Fig. 1. Pyramid plot to display the effect sizes (Cohen’s d) of protein significantly (P = <0.05) associated with A burden (A− versus A+). On the right are proteins 
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At the univariate level, prothrombin (or coagulation factor II) was 
shown to be decreased in A+ individuals but had a modest effect 
size. Multiple lines of evidence support that cerebrovascular disease 
may play a role in AD and that A may be involved in thrombosis, 
fibrinolysis, and inflammation via its interaction with the coagula-
tion cascade (13). The APP isoform Kunitz protease inhibitor domain 
(protease nexin-2) is involved in the regulation of coagulation and 
in thrombosis pathophysiology (14, 15). Thrombin has previously 
been reported to induce the release of APP from platelets and its sub-
sequent processing (16), and we have previously reported fibrinogen 
gamma chain, a protein involved in the intrinsic coagulation cascade 
and target of prothrombin, as having a modest prediction of A pos-
itivity (17). However, this study did not replicate our previous find-
ing. Encouragingly, our study has highlighted the most investigated 
current plasma biomarkers for AD and/or neurodegeneration, APP 
and NfL, in an unbiased fashion. These proteins are included in 
both A burden prediction models but have a greater effect size in 
the classifier that included individuals with reported cognitive de-
cline, confirming their connection with the more established dis-
ease state. A, derived from APP, is readily measured in plasma, but 
historically, the correlation with AD and/or surrogate A measures 
has been absent or weak (18). Plasma A concentrations have been 
interpreted as influenced by production in platelets and other extra-
cerebral tissues (19). However, recent MS studies suggest that a ratio 
of APP-derived fragments (APP669–711 and A42/A40) identifies A+ 
individuals with high sensitivity and specificity (6). In part, our data 
agree with these studies and with prior work that found plasma APP 
species to be elevated in AD and implicated serine proteases in these 
changes (20). We have shown that combined intensities from tryptic 
peptides residing from similar APP fragment regions, as the studies 
described above were shown to be statistically related to A PET, 
although large overlap between groups remained. As with other 
panel-based studies, we also conclude that APP peptides (including 
A species) have the utility to contribute to a compound panel 
(9, 21). NfL is an axonal neuron-specific protein actively involved in 
the pathogenesis of axonal injury and degeneration. NfL is detect-
able and quantifiable in blood despite being more than 50-fold lower 
in concentration than in the CSF (22), and here, we have demon-
strated NfL peptide measurements using an untargeted MS approach. 
In previous studies, NfL levels in blood have been found to be in-
creased in AD (23), frontotemporal dementia (24), and progressive 
supranuclear palsy (25). CSF and plasma concentrations correlate, 
supporting the notion that plasma NfL reflects CSF concentration 
and potentially CNS damage (26). NfL, after APP and NGN2, was 
Table 3. GLM-adjusted protein groups significantly associated with A SUVR in cognitively unimpaired participants stratified by A+/− classification 
after multiple testing correction. Protein groups were also associated with A SUVR with an adjustment for APOE genotype. All protein groups that are 
nominally associated with A in cognitively unimpaired (P > 0.05) are shown in table S1. 
UniProt ID Protein group description A+ group
Adjusted for APOE 4 status
t Mean difference P value Q t
Mean 
difference P value Q value
P05067 APP ↑ −5.651 −0.290 4.57 × 10−08 2.08x10−05 −4.686 −0.241 4.71 × 10−06 0.001
Q9H2A3 NGN2 ↑ −5.556 −0.319 7.43 × 10−08 2.08x10−05 −4.787 −0.276 2.99 × 10−06 0.001
P07196 NfL ↑ −4.639 −0.229 5.80 × 10−06 0.001 −3.716 −0.184 2.53 × 10−04 0.047
O95704 APBB3 ↑ −4.389 −0.274 1.71 × 10−05 0.002 −3.374 −0.210 0.001 ns
Q13127 REST ↓ 3.570 0.142 4.33 × 10−04 0.048 3.385 0.135 0.001 ns
Table 4. GLM-adjusted protein groups significantly associated with A SUVR in all subjects stratified by A+/− classification after Benjamini-Hochberg 
multiple testing corrections. Protein groups were also associated with A SUVR with an adjustment for APOE genotype. All protein groups that are nominally 
associated with A (P > 0.05) are shown in table S2 (A and B). 
UniProt ID Protein group description A+ group
Adjusted for APOE 4 status
t Mean difference P value Q t
Mean 
difference P value Q value
P05067 A A4 protein ↑ −6.419 −0.279 5.79 × 10−10 3.24 × 10−07 −5.019 −0.220 9.22 × 10−07 0.001
Q9H2A3 NGN2 ↑ −5.702 −0.283 2.98 × 10−08 8.34 × 10−06 −4.624 −0.231 5.75 × 10−06 0.002
P07196 NfL ↑ −5.258 −0.219 2.88 × 10−07 5.38 × 10−05 −3.928 −0.164 1.08 × 10−04 0.015
O95704 APBB3 ↑ −5.189 −0.272 4.05 × 10−07 5.67 × 10−05 −3.710 −0.194 2.49 × 10−04 0.028
Q13127 REST ↓ 4.247 0.143 2.94 × 10−05 3.29 × 10−03 3.984 0.135 8.64 × 10−05 0.015
P81274 GPSM2 ↓ 4.016 0.124 7.61 × 10−05 0.007 3.564 0.111 4.28 × 10−04 0.040
Q13103 SPP2 ↓ 3.833 0.108 1.56 × 10−04 0.013 3.310 0.094 0.001 0.084
Q8IVF4 DNAH10 (axonemal) ↑ −3.548 −0.090 4.54 × 10
−04 0.032 −3.165 −0.081 0.002 0.120
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the most statistically significant finding in our study. We found a 
highly significant association between NfL and A burden, in keep-
ing with previous studies, although we do not find an age-related 
increase of plasma NfL (23). As previously hypothesized by others, 
it is likely that observed elevation of plasma NfL has been included 
in our prediction classifier(s) as a reflection of CNS injury and not 
that of A burden itself, even at the preclinical stage. Nonetheless, as 
the amyloid cascade hypothesis suggests that A deposition is the 
main initiator behind events that result in neurodegeneration, ele-
vations of NfL in response to A burden, if present, would be an 
expected observation.
Novel markers of A burden highlighted by this panel study 
include NGN2, FHAD1, and DNAH10, although further work 
will be needed to determine the mechanistic relationship between 
these proteins with A pathogenesis and AD. Furthermore, two 
protein groups were specifically associated with A burden in 
cognitively unimpaired individuals (GPR115 and RPS6KA3). 
GPR115 was the second most important feature, after prothrombin, 
offering it as a potential marker of early A deposition. Numerous 
studies have presented evidence that implicate G protein–coupled 
receptors in the pathogenesis of AD and in multiple stages of the 
hydrolytic processing of APP (27). At the univariate level, NGN2 
was highly associated with A, with a larger effect size in the 
cognitively unimpaired group. NGN2 is a bHLH transcription 
factor that was first identified for its ability to promote neuronal 
differentiation in brain and spinal cord (28). NGN2 also speci-
fies phenotypic features of neurons and regulates axonal guidance 
(29). NGN2 has been found to correlate with APP expression by 
Fig. 2. Protein classifier to predict A positivity in cognitively unimpaired individuals. (A) Graph showing the AUC statistic of the 50 classifier models produced using 
the “cognitively unimpaired cohort” training dataset. The AUC when testing each classifier model in the training dataset is in black, and the AUC when testing the classifier 
model in the testing dataset (KARVIAH) is in orange. On the x axis is the number of features used in each classifier model. For the classifier with the best AUC in the testing 
dataset (this was the classifier that used 12 features; Table 5), three graphs access the classifier’s performance: (B) ROC curve, (C) sensitivity and specificity plotted in black 
and orange, respectively, and (D) PPV and NPV plotted in black and orange, respectively.
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an increase in APP transgenic mice (Tg2576) but significantly 
down- regulated in neural stem/progenitor cells from APP 
knockout mice (30). In addition, a close relationship between 
NGN2 and APP was found in our study, but the origin of our 
NGN2 expression is unclear as limited information is available 
about peripheral NGN2.
A biologically complex neurodegenerative disease such as AD is 
unlikely to be caused by a single pathogenic event (31), and the find-
ing of a panel of plasma biomarkers characterizing AD pathology, 
rather than a single marker, was to be expected. What was encour-
aging was the high performance and reproducibility of the trained 
model in an entirely independent cohort, despite a methodically 
Table 5. Feature list for multianalyte classifier predicting elevated A burden in cognitively unimpaired cohort. The classifier was training in the AIBL 
cohort (n = 144), achieving a testing AUC of 0.891 in the KARVIAH cohort (n = 94). GPCR, G protein–coupled receptor; sens, sensitivity; spec, specificity. 
Feature 
no.
Cognitively unimpaired classifier for A burden
(Testing AUC = 0.891, sens = 0.78, spec = 0.77, NPV = 0.68, PPV = 0.85)
UniProt ID Feature description Tryptic amino acid peptide sequences contributing to protein scores
1 P00734 Prothrombin 87–94, 98–116, 125–133, 178–198, 199–224, 217–224, 225–243, 248–263, 315–327, 328–344, 345–363, 354–363, 441–447, 447–452, 467–468, 518–537, 544–560, and 560–575
2 Q8IZF3 Adhesion GPCR F4 100–107, 315–328, 657–689, and 673–698
3 P05067 A A4 protein 677–687 and 688–699
4 Q9H2A3 NGN2 114–120
5 n/a APOE 4 count n/a
6 Q8IVF4 DNAH10 (axonemal)
207–223, 528–540, 879–915, 1133–1148, 1524–1528, 1870–1927, 2404–2436, 2906–2941, 2923–2945, and 
4100–4139
7 Q13127 REST 353–369, 727–742, and 882–896
8 P07196 NfL 137–144, 154–164, 318–331, and 447–462
9 P51812 RPS6KA3 80–100, 109–132, 193–216, 226–242, 274–282, 508–525, and 570–591
10 P81274 GPSM2 267–278, 318–347, and 422–433
11 B1AJZ9 FHAD1 861–868, 876–887, 897–905, 931–942, 1030–1052, 1059–1070, and 1104–1139
12 n/a Age of participant n/a
Table 6. Feature list for multianalyte classifier predicting elevated A burden in a mixed diagnosis cohort. The classifier was training in the AIBL cohort 
(n = 169), achieving a testing AUC of 0.905 in the KARVIAH cohort (n = 94). 
Feature no.
Mixed diagnosis classifier for A burden
(Testing AUC = 0.904, sens = 0.81, spec = 0.80, NPV = 0.72, PPV = 0.87)
UniProt ID Feature description Tryptic amino acid peptide sequences contributing to protein scores
1 n/a APOE 4 count* n/a
2 P05067 A A4 protein* 677–687 and 688–699
3 P07196 NfL* 137–144, 154–164, 318–331, and 447–462
4 Q9H2A3 NGN2* 114-120
5 Q8IVF4 DNAH10 (axonemal)*
207–223, 528–540, 879–915, 1133–1148, 1524–1528, 1870–1927, 2404–2436, 2906–2941, 
2923–2945, and 4100–4139
6 Q13127 REST* 353–369, 727–742, and 882–896
7 O95704 APBB3 155–175 and 414–430
8 P81274 GPSM2* 267–278, 318–347, and 422–433
9 P00734 Prothrombin* 87-94, 98–116, 125–133, 178–198, 199–224, 217–224, 225–243, 248–263, 315–327, 328–344, 345–363, 354–363, 441–447, 447–452, 467–468, 518–537, 544–560, and 560–575
10 B1AJZ9 FHAD1* 861–868, 876–887, 897–905, 931–942, 1030–1052, 1059–1070, and 1104–1139
*Proteins also included in the classifier for predicting A in the cognitively unimpaired individuals.
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complex procedure. Previous studies have used shotgun MS as a 
hypothesis-generating tool to identify plasma protein biomarkers 
of AD pathology (7, 8, 17, 32). In each of these occasions, an attempt 
was then made to replicate these markers on an orthogonal platform, 
typically an immuno-based assay [e.g., enzyme-linked immuno-
sorbent assay (ELISA) or Luminex xMAP]. In these cases, translation 
between techniques has been relatively disappointing and is likely 
due to key platform differences. Untargeted proteomics by MS in-
volves the analysis of peptides resulting from denatured proteins, 
while ELISA measures native protein or, more precisely, the region 
of the intact protein where the epitope is recognized by the antibody 
resides. Therefore, using different methods will inevitably lead to 
different results, and this may contribute to why proteins identified 
by an untargeted approach fail in replication using a targeted ap-
proach. To our knowledge, this is the first time that a multianalyte 
plasma biomarker panel for an AD-related phenotype has been 
found and independently replicated by a nontargeted MS approach, 
and the commonality in platform, and certainly the homology in 
sample preprocessing, between discovery and replication has con-
tributed to this successful result.
There are limitations to this study. First, although generating 
promising results, the platform used cannot be used as a routine 
tool, although we have demonstrated it to be robust in an indepen-
dent cohort. Interlaboratory standardized operating procedures for 
Fig. 3. Protein classifier to predict A positivity that includes participants with MCI and AD. (A) Graph showing the AUC statistic of the 50 classifier models produced 
using the “mixed diagnosis cohort” training dataset. The AUC when testing each classifier model in the training dataset is in black, and the AUC when testing the classifier 
model in the testing dataset (KARVIAH) is in orange. On the x axis is the number of features used in each classifier model. For the classifier with the best AUC in the testing 
dataset (this was the classifier that used 10 features; Table 6), three graphs access the classifier’s performance: (B) ROC curve, (C) sensitivity and specificity plotted in black 
and orange, respectively, (D) PPV and NPV plotted in black and orange, respectively.
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this analytical process would prove difficult, given the complexed 
and variable methodological stages. Efforts will need to be made, 
guided by the MS spectral data, to transform the panel to an alter-
native platform that is more appropriate for widespread implemen-
tation. Second, the proteins measured in this study have been 
inferred on the basis of the combination of peptides, where a selec-
tive reaction monitoring approach as a validation of specific peptides 
associated with A burden might be more appropriate. Further, it 
remains unclear whether the classifiers can track longitudinal 
changes in A, monitor A reduction in a therapeutic trial setting, 
or differentiate between other dementias that display A pathology. 
Last, cross- sectional studies have indicated that CSF A42 changes 
precede changes in A PET (33). This signifies that individuals with 
AD may be initially classified as “CSF+/PET−” before converting to 
“CSF+/PET+” at a later stage (34). Future studies could comple-
ment the endophenotype approach using PET measures of A 
load, with studies using CSF measures of both A42 and tau as 
the comparison variable.
In summary, using an unbiased MS approach, we have found and 
replicated with high accuracy, specificity, and sensitivity a plasma 
protein classifier reflecting A burden in a cognitively unimpaired 
cohort. These predictive panels highlighted novel and established 
markers for AD. These panels almost certainly need to be refined, 
simplified, and undoubtedly validated in independent cohorts. 
Furthermore, efforts need to be made to successfully translate this 
panel to a simpler automated platform suitable for wider utility. 
The prediction of A burden in preclinical AD using a blood-based 
measure offers great potential in preclinical stratification for clinical 
trials and future diagnostic management.
MATERIALS AND METHODS
Study cohorts, assessments, and biofluid procedures
The AIBL was used as the discovery cohort in the study. The AIBL 
study is a longitudinal study of aging, neuroimaging, biomarkers, 
lifestyle, and clinical and neuropsychological analysis, with a focus 
on early detection and lifestyle intervention (www.aibl.csiro.au). 
Specifics regarding participant recruitment, study design, and 
clinical assessments were previously described (35). Plasma samples 
from 190 AIBL participants with baseline A PET imaging (11C-PiB) 
were selected, with a focus on individuals without cognitive de-
ficits at baseline. Further details about the 11C-PiB imaging protocols 
for the AIBL cohort were previously described (36). Participants were 
categorized as A− and A+ based on the 11C-PiB SUVR cutoff of 
1.4 (37). For plasma preparation, whole blood (80 ml) was collected 
in the morning (overnight fasting) by venepuncture and centrifuged 
at 200g (20°C) for 10 min. The platelet-rich plasma was further 
spun at 800g (20°C) for 15 min (9). The KARVIAH was used as an 
independent replication cohort in this study. Participants recruited 
to this cohort were residents of Anglicare (Sydney, NSW, Australia), 
and all volunteers were required to meet the set screening inclu-
sion and exclusion criteria to be eligible for the KARVIAH cohort 
(38). Selection of 94 KARVIAH participants was dependent on 
the availability of 18FBB images for each subject, where an A SUVR 
cutoff score of 1.35 was used to categorize A− and A+ (39). All 
KARVIAH participants were cognitively unimpaired based on their 
Mini Mental State Examination score of >26. Plasma preparation 
for 94 KARVIAH participants followed the same protocol as AIBL 
participants.
Immunodepletion, enzymatic digestion, and tandem mass 
tag peptide labeling
All AIBL and KARVIAH samples were randomized before sample 
preparation. Albumin and immunoglobulin G immuno-depletion 
was achieved by a commercially available immunoaffinity column 
(ProteoPrep, Sigma-Aldrich) with a starting volume of 30 l. For 
enzymatic digestion, 100 g of immunodepleted sample was initially 
incubated with 100 mM triethylammonium bicarbonate (TEAB) and 
0.1% (w/v) SDS. Reduction and alkylation were achieved in 1 mM 
tris (2-carboxyethyl) phosphine for 1 hour at 55°C, followed by incu-
bation in 7.5 mM iodoacetamide. Protein samples were individually 
digested overnight in 4 g of trypsin (sequencing grade, Roche) 
reconstituted in 100 mM TEAB. TMT10plex reagents (Thermo 
Fisher Scientific), reconstituted in acetonitrile (ACN), were added 
to the appropriate samples and incubated for 1 hour at room tem-
perature (RT). Samples were treated with 5% hydroxylamine and 
incubated at RT for a further 15 min. For the 284 samples included 
in the study, a total of 32 “TMT10plex groups” were created by com-
bining nine clinical samples (AIBL or KARVIAH) and one study 
reference. The study reference was an equal contribution of all sam-
ples examined in the study. After combining, TMT10plex groups were 
incubated at RT for a further 15 min.
OFFGEL (OGE):Isoelectric peptide fractionation
Peptide separation was achieved using the 3100 OFFGEL Fraction-
ator (Agilent Technologies) with a 24-well setup. Immobilized pH 
gradient (IPG) gel strips (24 cm; GE Healthcare), with a 3 to 10 lin-
ear pH gradient, were rehydrated for 15 min. Before fractionation, 
TMT10plex groups were dried down and resuspended in OFFGEL 
stock solution. Next, 150 l of resuspended TMT10plex peptide sam-
ple was loaded into each compartment of the OFFGEL system. Peptide 
samples were focused until 50 kVh had accumulated (~48 hours). 
Liquid fractions were collected into separate Eppendorf tubes (pri-
mary recovery). To extract larger peptides retained within the IPG 
strips, 150 l of ddH20/ACN/formic acid (49:50:1) was added to 
each compartment and incubated for a further 30 min with occasional 
pipette mixing. The supernatant (secondary recovery) was retrieved 
and added to the primary recovery. Each fraction collection was 
purified by a SOLA horseradish peroxidase solid-phase extraction 
cartridge (10 mg/1 ml; Thermo Fisher Scientific) before evapora-
tion by centrifugation under a vacuum.
MS (LC-MS/MS) analysis
Before liquid chromatography–tandem MS (LC-MS/MS) analysis, 
each OFFGEL peptide fraction was reconstituted in ddH20/ACN/
formic acid (50:49.9:0.1) and then shaken at 37°C and vortexed 
thoroughly. Chromatographic separation and mass spectra acquisi-
tion (LTQ Orbitrap Velos Pro, Thermo Fisher Scientific) was per-
formed on each fraction and was previously described (17), with a 
modified MS1 resolution of 60,000 and MS2 resolution of 30,000.
Preprocessing of MS (LC-MS/MS) data
Raw MS data for all fractions within a single TMT10plex were com-
bined and searched as a “MudPIT” against the human UniProtKB/
Swiss-Prot database using Mascot and Sequest (Proteome Discov-
erer version 1.4). The criteria for Mascot were described elsewhere 
(17) and Sequest also followed these settings. Peptide spectrum 
matches (PSMs) were rejected if identified with only low confidence 
(≥5% FDR) and/or missing quantification channels [e.g., not all 
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peaks for tandem mass tags (TMTs) visible in spectra]. Raw inten-
sity values of TMTs from PSMs passing filters were used for quantifi-
cation. Preprocessing steps were applied to translate PSM intensities to 
relative protein abundance. This was a three-step process and was mod-
ified from a previously described R script (PRQ, or Pre- processing 
for Relative Quantification) (17). First, sequences with an intensity <50 
were removed from the analysis. Second, median normalization within 
each TMT10plex was applied. This was achieved by calculating the 
ratio between all the intensities within a sample and the correspond-
ing reference sample and then dividing each intensity by the calcu-
lated ratio, obtaining an intensity ratio. Each intensity ratio is, in 
turn, divided by the corresponding reference sample, and all results 
corresponding to the same peptide were summed into a peptide score. 
Third, the mean peptide scores are calculated to obtain protein abun-
dance measurements. Last, a protein matrix table was then produced, 
which collated all identified protein groups and their corresponding 
TMT scores for each individual across the whole study. A protein 
group is defined as proteins that are identified by the same set or 
subset of assigned peptides.
Statistical analysis
Principal components analysis demonstrated a significant variation 
in protein abundance scores between the 32 TMT10plex groups. 
Many experimental factors are intrinsic with TMT10plex group: 
off-gel electrophoresis (OGE) fractionation date, TMT labeling 
date, and date of MS acquisition, which are prone to significant 
variation. Therefore, an initial generalized linear model (GLM) 
correcting for only TMT10plex group was performed before further 
investigating the effect of other covariates on protein group ratios. 
All GLM protein abundance scores were then log10-transformed to 
achieve normal distribution. Covariates including age, gender, and 
center (AIBL or KARVIAH) were investigated. We found that most 
proteins were significantly affected by these covariates, and therefore, 
subsequent GLM to include these confounders was appropriate. 
Missing protein abundance observations were imputed with the 
R package “mice” (version 2.46.0) using four imputations, four itera-
tions, and 50 other proteins as a predictor. The 50 predictor pro-
teins were chosen using the feature selection method LASSO via the 
R package “glmnet” (version 2.0-13) (40) with an  penalty cost of 1, 
the result of which was a list of proteins ranked by their correlation 
with the protein to impute; the top 50 predictor proteins were se-
lected from this list.
Univariate analysis
Univariate analysis specializes on finding proteins that, by themselves, 
correlate with a given outcome once the effect of a number of covari-
ates is eliminated. This analysis was performed in SPSS version 24 
(IBM). For univariate analysis only, AIBL and KARVIAH samples 
were combined for the association with A PET. All univariate analyses 
were performed on the imputed GLM-adjusted data described above. 
Student’s t test and Pearson’s correlation were performed to assess 
protein abundances with A as a binary (A+/−) and continuous 
measure (SUVR). A partial correlation and binary logistic regression 
were also performed to examine the influence of APOE genotype 
on the results. Benjamini-Hochberg Q values were calculated as 
a multiple testing correction. This univariate pipeline was performed 
for two datasets: (i) those classified as cognitively unimpaired (n = 238; 
Table 1) and (ii) all individuals included in the study, including 
those with MCI and AD (n = 284; Table 2).
Multivariate biomarker classifier
In the case of our study, and given a large set of proteins and an 
outcome, multivariate analysis specializes on finding which is the 
combination of proteins that best predicts the outcome. Many, but 
not necessarily all, of these proteins will also correlate with the out-
come by themselves. All analyses in this section were performed using 
R (version 3.3.3). For the purpose of multianalyte classification of 
A positivity, imputed protein abundances that were only GLM ad-
justed for TMT10plex group were used, thus allowing demographic 
variables to be independently chosen in feature selection. GLM was 
achieved using the R package “stats” (version 3.3.3).
Biomarker classifier development took place in three steps: (i) 
feature selection, (ii) training, and (iii) testing. Feature selection and 
training used only the AIBL cohort, while the KARVIAH cohort was 
kept for independent testing. Two training datasets were created, 
cognitively unimpaired individuals (n = 144; Table 1) and one in-
cluding those with MCI and AD (n  =  169; Table  2). This format 
would allow us to observe the influence of disease on the ability of a 
classifier model to predict A positivity. The testing dataset contained 
a total of 94 samples from KARVIAH (Table 1). Two feature sets were 
used, either demographic variables only (gender, age at sampling, and 
APOE ɛ4 status) or both demographic and protein scores. Analysis 
was performed four times, each with a different combination of train-
ing dataset and feature set. For each analysis, the aforementioned 
three steps (feature selection, training, and testing) were performed 
over 50 iterations, where, in each iteration, the algorithm was allowed 
to use one protein more than in the previous iteration, starting with 
1 protein and finishing with 50. Feature selection was performed 
using a training dataset and the R package glmnet (version 2.0-13) 
(40) with an  penalty cost of zero (“Ridge regression”), this result-
ed in a list of features ranked by their correlation with A positivity, 
of which the top x was selected for subsequent training (where x = 
iteration number). Training was performed using the selected fea-
tures, the same training dataset, and SVM from the R package “e1071” 
(version 1.6-8), this resulted in a model to classify A positivity. 
Testing involved evaluating the accuracy at which the classifier could 
predict A positivity in the testing dataset (KARVIAH); this was 
achieved by calculating the AUC using the R package “ROCR” (version 
1.0.7). The training and testing AUC of all 50 classifiers was plotted 
using the R package “ggplot2” (version 2.2.1). Following these three 
steps, we selected the classifier with the highest AUC in the testing 
dataset as the best performing, and to assess this further, we used 
ROCR to calculate six statistics for a range of cutoff values and plotted 
these over three images using ggplot2. These statistics included the 
true positive rate, false positive rate, sensitivity, specificity, PPV, and 
NPV. The best cutoff value was chosen as the intersection of the 
sensitivity and specificity.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/5/2/eaau7220/DC1
Table S1. Residual scores for all 560 protein groups.
Table S2. The association of plasma protein groups with A SUVR in cognitively unimpaired 
subjects.
Table S3. The association of plasma protein groups with A SUVR in all subjects.
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